Biological Characterization of Yellow Fever Viruses Isolated From Non-human Primates in Brazil With Distinct Genomic Landscapes

Furtado, Nathália Dias; Raphael, Lidiane de Menezes; Ribeiro, Ieda Pereira; Mello, Iasmim Silva de; Fernandes, Déberli Ruiz; Gómez, Mariela Martínez; Santos, Alexandre Araújo Cunha dos; Nogueira, Mônica da Silva; Castro, Márcia Gonçalves de; Abreu, Filipe Vieira Santos de; Martins, Lívia Carício; Vasconcelos, Pedro Fernando da Costa; Lourenço‐de‐Oliveira, Ricardo; Bonaldo, Myrna C.

doi:10.3389/fmicb.2022.757084

Cited by 8 publications

(16 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We selected two final antibodies (MBL-YFV-01 and MBL-YFV-02) that did not compete with each other and neutralized 100% of YFV-ES504 at < 125 ng/mL, then assessed their capacity to neutralize three additional primary isolates from Brazil (YFV-4408-1E, YFV-RJ155, and YFV-GO09) (Table 2). These strains were chosen because they were isolated during different outbreaks ( 10 ). YFV-4408-1E was isolated from a YFV-infected howler monkey in 2008 in Rio Grande do Sul state.…”

Section: Resultsmentioning

confidence: 99%

Therapeutic neutralizing monoclonal antibody administration protects against lethal Yellow Fever infection

Ricciardi

Rust

Pedreño-López

et al. 2022

Preprint

View full text Add to dashboard Cite

Few countermeasures to treat Yellow Fever virus (YFV) infection are under development, because vaccines have helped to limit new infections. Unfortunately, vaccine hesitancy, supply deficits, and a paucity of therapeutic options have left individuals at risk. Here, we tested potent YFV-specific neutralizing monoclonal antibodies in rodents and non-human primates. We administered antibodies during acute pathogenic YFV infection and demonstrate that we can prevent severe disease and death. Given the severity of YFV-induced disease, our results show that these antibodies could be effective in saving lives and fill a much-needed void in managing Yellow Fever cases during outbreaks around the world.

show abstract

Section: Resultsmentioning

confidence: 99%

Therapeutic neutralizing monoclonal antibody administration protects against lethal Yellow Fever infection

Ricciardi

Rust

Pedreño-López

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…The plaque phenotype assay was conducted as described elsewhere [ 45 ]. In summary, Vero cells seeded at 40,000 cells/cm 2 were infected with 10 PFU, 20 PFU, and 40 PFU of each virus.…”

Section: Methodsmentioning

confidence: 99%

“…The cell medium was discarded, and the inocula were adsorbed in the cell monolayer for 1 h. After that, the viral suspension was discarded, the appropriate cell medium was added to the monolayer, and the cells were incubated for 5 days. An aliquot of cell supernatant was collected every 24 h and titrated by plaque assay [ 45 ]. The viral titers were transformed in log 10 and plotted in a dispersion graph for analysis.…”

Section: Methodsmentioning

confidence: 99%

Amino Acid Polymorphisms on the Brazilian Strain of Yellow Fever Virus Methyltransferase Are Related to the Host’s Immune Evasion Mediated by Type I Interferon

Furtado

Mello

Godoy³

et al. 2023

Viruses

Self Cite

View full text Add to dashboard Cite

Since late 2016, a yellow fever virus (YFV) variant carrying a set of nine amino acid variations has circulated in South America. Three of them were mapped on the methyltransferase (MTase) domain of viral NS5 protein. To assess whether these changes affected viral infectivity, we synthesized YFV carrying the MTase of circulating lineage as well as its isoform with the residues of the previous strains (NS5 K101R, NS5 V138I, and NS5 G173S). We observed a slight difference in viral growth properties and plaque phenotype between the two synthetic YFVs. However, the MTase polymorphisms associated with the Brazilian strain of YFV (2016–2019) confer more susceptibility to the IFN-I. In addition, in vitro MTase assay revealed that the interaction between the YFV MTase and the methyl donor molecule (SAM) is altered in the Brazilian MTase variant. Altogether, the results reported here describe that the MTase carrying the molecular signature of the Brazilian YFV circulating since 2016 might display a slight decrease in its catalytic activity but virtually no effect on viral fitness in the parameters comprised in this study. The most marked influence of these residues stands in the immune escape against the antiviral response mediated by IFN-I.

show abstract

“…Yellow fever virus (YFV) is transmitted by the Aeges aegytpi mosquito causing Yellow Fever and while vaccination is available, the virus is continuing to spread to areas of the world where vaccination is not prevalent [ 126 ]. YFV is an enveloped virus with a positive-sense, single-stranded RNA genome.…”

Section: Surface Tlr Associated Virus Interactionsmentioning

confidence: 99%

“…YFV is an enveloped virus with a positive-sense, single-stranded RNA genome. Three structural proteins are encoded by YFV including capsid (C), membrane (prM/M), and envelope (E) along with 7 non-structural proteins [ 126 ]. Modhiran et al identified that NS1 from several Flaviviridae , including YFV, induced the secretion of IL-6 and that this response was likely mediated by TLR4 in PBMCs ( Figure 4 ) [ 107 ].…”

Section: Surface Tlr Associated Virus Interactionsmentioning

confidence: 99%

Scratching the Surface Takes a Toll: Immune Recognition of Viral Proteins by Surface Toll-like Receptors

Hatton

Guerra

2022

Viruses

View full text Add to dashboard Cite

Early innate viral recognition by the host is critical for the rapid response and subsequent clearance of an infection. Innate immune cells patrol sites of infection to detect and respond to invading microorganisms including viruses. Surface Toll-like receptors (TLRs) are a group of pattern recognition receptors (PRRs) that can be activated by viruses even before the host cell becomes infected. However, the early activation of surface TLRs by viruses can lead to viral clearance by the host or promote pathogenesis. Thus, a plethora of research has attempted to identify specific viral ligands that bind to surface TLRs and mediate progression of viral infection. Herein, we will discuss the past two decades of research that have identified specific viral proteins recognized by cell surface-associated TLRs, how these viral proteins and host surface TLR interactions affect the host inflammatory response and outcome of infection, and address why controversy remains regarding host surface TLR recognition of viral proteins.

show abstract

Biological Characterization of Yellow Fever Viruses Isolated From Non-human Primates in Brazil With Distinct Genomic Landscapes

Cited by 8 publications

References 54 publications

Therapeutic neutralizing monoclonal antibody administration protects against lethal Yellow Fever infection

Therapeutic neutralizing monoclonal antibody administration protects against lethal Yellow Fever infection

Amino Acid Polymorphisms on the Brazilian Strain of Yellow Fever Virus Methyltransferase Are Related to the Host’s Immune Evasion Mediated by Type I Interferon

Scratching the Surface Takes a Toll: Immune Recognition of Viral Proteins by Surface Toll-like Receptors

Contact Info

Product

Resources

About